ArticleFrontiers in medicine2025
The efficacy of low-level laser therapy in alleviating genitourinary syndrome of menopause and stress urinary incontinence: the pilot study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Evaluation of photobiomodulation therapy for genitourinary syndrome of menopause: A single-center prospective study.PloS one · 2026Trial
- Electrotherapy Plus Photobiostimulation for the Treatment of Mild Pelvic Organ Prolapse and Stress Urinary Incontinence.Journal of clinical medicine · 2026Article
- Laser for lower-urinary tract symptoms.Journal of the Chinese Medical Association : JCMA · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Genitourinary syndrome of menopause (GSM) and stress urinary incontinence (SUI) are prevalent among women. While low-level laser therapy (LLLT) has been employed for wound healing, no studies have explored its effectiveness in treating GSM and SUI. Methods: Between September 2022 and August 2023, all women received LLLT for GSM and SUI at the gynecologic outpatient clinic of a hospital were retrospectively reviewed. The treatment was administered once a week for 8 weeks. Vaginal Health Index (VHI) and pre- and post-treatment questionnaires were utilized to assess lower urinary tract symptoms (LUTS). Results: A total of 41 women were enrolled, including 24 (59%) with SUI and 22 (52%) with GSM (5 women reported both conditions). Significant improvements were observed in all VHI items for both groups. Total scores for ICIQ-SF (International Consultation on Incontinence Questionnaire-Short Form), UDI-6 (Urogenital Distress Inventory-6), IIQ-7(Incontinence Impact Questionnaire-7), USS (Urgency Severity Scale), and OABSS (Overactive Bladder Symptom Score) demonstrated significant enhancements in all women and specifically in the GSM group. In the SUI group, USS and OABSS significantly improved, with more domains in KHQ (King's Health Questionnaire) showing improvement compared to the GSM group. In the GSM group, lubrication, pain, and the total score of FSFI (Female Sexual Function Index) improved significantly, while no significant enhancement in sexual function was observed in the SUI group. Conclusion: This pilot study indicates that LLLT is a safe, cost-effective, and straightforward treatment for alleviating GSM and SUI symptoms. Women with GSM experienced improvements in LUTS and sexual function, while women with SUI demonstrated improvements in urinary urgency and LUTS-related quality of life. This study represents the first application of LLLT in gynecology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.